Full history for every metric is available with a Kvantra account
Starcoin Group Limited (0399.HK)
Key financial summary
Financials in HKD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | HKD m | 15 | 15 | 11 | 8 | 7 | 2 | 2 |
| Operating profit | HKD m | -13 | -24 | |||||
| Net profit | HKD m | -408 | -396 | 297 | -246 | 103 | -346 | -564 |
| EPS reported | HKD | -0.20 | -0.32 | |||||
| Operating cashflow per share | HKD | -0.01 | 0.00 | |||||
| Capex per share | HKD | 0.00 | 0.00 | |||||
| FCF per share | HKD | -0.01 | 0.00 | |||||
| Free cash flow | HKD m | -11 | 3 | |||||
| Net debt | HKD m | 1,000 | 1,072 | |||||
| Book value equity | HKD m | -681 | -784 | |||||
| Book value per share | HKD | -0.39 | -0.40 | |||||
| Number of shares | m | 1,728.7 | 1,946.94 | |||||
| DPS (TTM paid) | HKD | 0.00 | 0.00 |
Financial summary
Financials in HKD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | -0.44 | -0.21 | |||||
| P/S LTM | x | 143.85 | 72.71 | |||||
| P/FCF LTM | x | -28.50 | 65.38 | |||||
| EV/EBITDA LTM | x | -4.19 | -78.68 | |||||
| EV/Sales LTM | x | 621.98 | 545.26 | |||||
| Earnings Yield LTM | % | -115.01% | -396.92% | |||||
| FCF Yield | % | -3.51% | 1.53% | |||||
| Quality | ||||||||
| ROE | % | 50.78% | 76.98% | |||||
| ROIC | % | -1.29% | -2.33% | |||||
| Operating margin | % | -634.29% | -1049.8% | |||||
| Gross margin | % | 8.99% | 14.46% | |||||
| FCF/Sales | % | -504.78% | 111.20% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -68.28% | -49.17% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.01 | 0.00 | |||||
| Net Debt/EBITDA | x | -3.22 | -68.19 | |||||
| EBIT/Net interest | x | -0.05 | -0.10 | |||||
| Net debt/market cap | % | 332.38% | 649.95% | |||||
| Net debt/Equity | x | -1.47 | -1.37 | |||||
| Gross debt/equity | x | -1.47 | -1.39 | |||||
Company overview
Operating as an investment holding company, Innovative Pharmaceutical Biotech Limited (IPBL) primarily engages in the distribution of beauty equipment and associated products across both mainland China and Hong Kong. The firm structures its operations into two key divisions: Trading of Beauty Products and Research and Development. Furthermore, IPBL's diversified activities include securities investments, the development and market introduction of oral insulin products, the provision of bio-industrial goods, and offering genetic screening services. The company rebranded to Innovative Pharmaceutical Biotech Limited in September 2015, having previously been known as United Gene High-Tech Group Limited. Its principal office is located in Sheung Wan, Hong Kong.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Starcoin Group Limited (0399.HK)
Operating as an investment holding company, Innovative Pharmaceutical Biotech Limited (IPBL) primarily engages in the distribution of beauty equipment and associated products across both mainland China and Hong Kong. The firm structures its operations into two key divisions: Trading of Beauty Products and Research and Development. Furthermore, IPBL's diversified activities include securities investments, the development and market introduction of oral insulin products, the provision of bio-industrial goods, and offering genetic screening services. The company rebranded to Innovative Pharmaceutical Biotech Limited in September 2015, having previously been known as United Gene High-Tech Group Limited. Its principal office is located in Sheung Wan, Hong Kong.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free